#Scalar #Field #Therapy and #Mitigation of #Seizure #Disorder: A Case Report

#Honolulu, #Hawaii, #USA, February 3rd, 2025

This case report describes a 4 year and 10 month old child with autism and intractable epilepsy who experienced frequent tonic clonic and partial seizures despite medication. After repeated sessions of scalar field therapy using the Energy Enhancement System, seizure frequency and duration were significantly reduced, with generalized seizures largely eliminated. While causality cannot be confirmed, the results suggest scalar field therapy may merit further study as a non pharmaceutical adjunct for pediatric seizure management.

Abstract

This case report examines the potential effects of scalar field therapy on seizure activity in a pediatric patient diagnosed with autism spectrum disorder and intractable epilepsy. The patient, a 4 year and 10 month old female, experienced a longstanding history of frequent tonic clonic and partial seizures despite ongoing pharmacological treatment. Following repeated exposure to a scalar field generated by the Energy Enhancement System (EES), the patient demonstrated a marked reduction in both seizure frequency and duration. Over time, generalized tonic clonic seizures were largely eliminated, with only brief partial seizures persisting. Although this single case does not establish causality, the observed improvement suggests that scalar field therapy may warrant further investigation as a non pharmaceutical adjunctive approach for #seizure #management, particularly in pediatric patients for whom medication side effects are burdensome.

Introduction

Seizure disorders affect approximately 2 to 3 #percent of #children worldwide, with significantly higher prevalence among individuals diagnosed with #autism #spectrum #disorder (#ASD). Studies estimate that up to 38 percent of children with autism experience epilepsy, often presenting with early childhood onset and persistent seizure activity into adolescence. These seizures are frequently associated with developmental regression, intellectual disability, and reduced quality of life.

Conventional management of pediatric epilepsy relies primarily on antiepileptic drugs, dietary interventions, and, in select cases, surgical or neurostimulation therapies. While pharmacological treatments can be effective, they are often accompanied by adverse effects such as sedation, fatigue, mood changes, and cognitive impairment—effects that may be particularly detrimental in children with neurodevelopmental disorders.

Given these limitations, there is growing interest in non invasive, non pharmaceutical approaches that may complement standard medical care. This report describes a case in which scalar field therapy was associated with a substantial reduction in seizure frequency and severity in a young child with autism and treatment resistant epilepsy.

Case Report

Patient Information

The patient was a 4 year and 10 month old female of Polynesian, Caucasian, and Asian descent with a three year history of autism spectrum disorder and seizure disorder, diagnosed by a pediatric neurologist. Her estimated developmental age was approximately two years.

For more than a year prior to presentation, the patient experienced six to eight generalized tonic clonic seizures daily, each lasting 10 to 20 seconds, along with eight to twelve brief partial or atonic seizures per day. Despite trials of multiple antiepileptic medications—including carbamazepine, topiramate, levetiracetam, lamotrigine, and methsuximide—seizure control remained inadequate, and medication side effects included excessive sedation.

#Medical #History

The patient was born at term following an uncomplicated pregnancy and vaginal delivery. Early developmental milestones were achieved ahead of schedule. However, around one year of age, she began to show signs of developmental regression, reduced social engagement, and diminished responsiveness.

At approximately 23 months of age, brief episodes of unresponsiveness were observed and later diagnosed as absence seizures. Over time, her seizure pattern evolved to include tonic clonic and drop seizures, with increasing frequency despite medication adjustments.

#Physical #Examination

At initial evaluation, the patient was non verbal and minimally communicative, with limited eye contact and inconsistent response to verbal commands. Motor function appeared intact, with adequate coordination and the ability to manipulate objects. No acute neurological deficits were observed outside of seizure activity.

Intervention: Scalar Field Therapy

The therapeutic intervention consisted of exposure to a scalar field generated by the Energy Enhancement System (EES). The system involves multiple generators positioned around a treatment room, designed to create a non directional energy field. Sessions lasted one to two hours, conducted two to three times per week.

During sessions, the patient remained fully clothed and was free to sit, lie down, play, eat, or sleep. No physical contact with equipment occurred. The patient’s mother supervised all sessions and maintained a detailed seizure log beginning one week prior to therapy initiation and throughout the treatment period.

Outcome Measures

Prior to treatment, the seizure log documented six to ten seizures per day, with durations ranging from 5 to 20 seconds. After the second treatment session, a reduction in both seizure frequency and duration was noted. Following the third session, the patient experienced her first seizure free day in over 18 months.

Over subsequent weeks, generalized tonic clonic seizures declined to fewer than one per week, and eventually ceased altogether. Partial or atonic seizures persisted but were reduced to four to five episodes per day, each lasting only one to two seconds. No changes were made to her medication regimen during the treatment period, and no adverse effects were reported.

At 6 month follow up, the reduction in seizure severity and frequency was largely sustained.

Discussion

The #clinical #improvement observed in this case was notable, particularly given the patient’s history of medication resistant epilepsy and the absence of changes to her pharmacological treatment. While spontaneous remission cannot be entirely ruled out, it is considered unlikely given the chronic and intractable nature of her condition.

#Placebo effects are also improbable, as the patient lacked awareness or expectation of therapeutic benefit. The temporal association between initiation of scalar field therapy and seizure reduction suggests a potential therapeutic effect that merits further investigation.

Proposed mechanisms for scalar field therapy include modulation of neuronal excitability, enhancement of cellular metabolism, improved blood rheology, and effects on neurotransmitter regulation. Experimental findings have suggested possible influences on noradrenaline reuptake and cellular electrical potential, both of which may impact seizure threshold. However, these mechanisms remain theoretical and require rigorous scientific validation.

Conclusion

This case report suggests that scalar field therapy may be associated with meaningful reductions in seizure frequency and severity in a child with autism and refractory epilepsy. While these findings are preliminary and limited to a single patient, they highlight the potential value of further controlled studies.

Future research should focus on randomized, double blind trials to evaluate efficacy, clarify underlying mechanisms, assess long term outcomes, and determine safety. If validated, scalar field therapy could represent a non invasive adjunctive option for seizure management, particularly for patients who experience significant side effects from conventional treatments.

Conflict of Interest Statement

Dr. Apau Ludlum and Dr. Harrigan report no conflicts of interest. Dr. Terry Shintani established an LLC to hold the Energy Enhancement System for liability and operational purposes but receives no financial compensation from the entity.

No external grant funding was received for this case report.

References

R. Canitano, “Epilepsy in autism spectrum disorders”, “European Child & Adolescent Psychiatry”, 2007, 16 (1) 61 through 66

American Academy of Pediatrics, “Diagnosis and management of autism spectrum disorder”, “Pediatrics“, 2001, 107 (5), 1221 through 1226

J. W. Wheless, D. F. Clarke, D. Carpenter, “Treatment of pediatric epilepsy: Expert opinion”, “Journal of Child Neurology”, 2005, 20 (Supplement 1), S 1 through S 56

N. Alvarez, F. Besag, M. Livanainen, “Antiepileptic drug use in intellectual disability”, “Journal of Intellectual Disability Research”, 1998, 42 (Supplement 1), 1 through 15

A. Puharich, “Proceedings of the United States Psychotronic Association Conference” 1988

E. Byrd, “Biological responses to scalar frequencies”, “Journal of the United States Psychotronics Association”, 1989, 2 (1)

G. Rein, “Biological interactions with scalar energy”, “Proceedings of the International Association for Psychotronics Research” 1988

P. Kwan, J. W. Sander, “Natural history of epilepsy”, “Journal of Neurology, Neurosurgery & Psychiatry”, 2004, 75 (10), 1376 through 1381

Authors

Noelani Apau Ludlum, Terry Shintani, Rosanne Harrigan, Department of Complementary and Alternative Medicine, John A. Burns School of Medicine, Honolulu, Hawaii, USA, Corresponding Authors Terry Shintani, Noelani Apau Ludlum, Rosanne Harrigan, Manuscript Accepted August 21st, 2012, Short Title “Scalar Field Therapy for Seizures”, DOI https://doi.org/10.4021/jnr134w 🔗 …

#ScalarFieldTherapy #SeizureDisorder #EpilepsyAwareness #AutismS

#NOW #KWS #ROSA #OWL #GT